Bladder cancer is unique among visceral malignancies in that urine, which can be easily obtained, has prolonged contact with bladder tumors. Urinary biomarkers offer the potential to provide insight into the host and tumor immune microenvironment to guide therapeutic strategies.
We evaluated the immune cellular composition of urine (urine-derived lymphocytes (UDLs)) versus tumor (tumor-infiltrating lymphocytes (TILs)).
We employed high-dimensional flow cytometry analyses on immune cells from tumors (TILs), urine (UDLs), and peripheral blood (peripheral blood mononuclear cells) among patients with bladder cancer. We performed multiplexed immunofluorescence (mIF) of matched tumors to provide spatial context to our findings, comparing deep/invasive and superficial/urine-facing regions of matched tumors.
Our findings suggest that the CD4+ and CD8+ T cell subsets of UDLs characterized by flow cytometry had similar phenotypic profiles to those found in TILs (cell clusters quantified by multidimensional scaling and differentiation states). Results of mIF imaging with a panel of phenotypic and functional T cell markers suggested that UDLs reflected TILs in both superficial and deep tumor sections. We also found sex-dependent patterns in TILs and UDLs, indicating the male bladder cancer tumor microenvironment is enriched in exhausted CD4+ and CD8+ T cells, while the female bladder cancer microenvironment is enriched for activated T cells.
Assessment of UDLs opens avenues of non-invasive biomarker development in clinical settings where bladder cancer TILs are hypothesized to predict clinical response. UDLs may also reflect sex-based differences in antitumor immunity.
Journal for immunotherapy of cancer. 2025 Oct 02*** epublish ***
Johanna M Schafer, No-Joon Song, Tong Xiao, Timothy D Gauntner, Kyeong Joo Jung, Emily G Fitts, Krishan Kumar, Hyeong Seon Jeon, Ryan A Elaoud, Kelsi Reynolds, Vincent M Caruso, Trevor G Levin, David McConkey, Cheryl T Lee, Kamal S Pohar, Steven K Clinton, William Carson, Dongjun Chung, Zihai Li, Debasish Sundi
Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA., Department of Computer Science, The Ohio State University, Columbus, Ohio, USA., The Ohio State University, Columbus, Ohio, USA., Convergent Genomics Inc, South San Francisco, California, USA., Johns Hopkins Medicine, Baltimore, Maryland, USA., Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA .
PubMed http://www.ncbi.nlm.nih.gov/pubmed/41043854